Swiss Federal Institute of Technology

Global Virus Network’s Top Virologists Partner with Monaco to Advance Pandemic Preparedness Across EU Countries

Retrieved on: 
Friday, October 20, 2023
Global Virus Network, Big data, Artificial intelligence, Disease, Risk, Partnership, Public, AI, Citizen science, Hospital, Infection, Swiss Federal Institute of Technology, Medical research, SARS-CoV-2, Vaccine, HIV, CSM, University, United States National Library of Medicine, WHO, Duke–NUS Medical School, Data collection, Research, Prince, Politics, COVID, World Health Organization, Travel, Privacy, Rega Institute for Medical Research, European Bioinformatics Institute, Climate change, National library, Swiss Federal Institute of Aquatic Science and Technology, GVN, Virus, Genomics, Casino, Pharmaceutical industry, Medical device

Prince Albert II of Monaco, among other dignitaries including from the World Health Organization (WHO) and the GVN.

Key Points: 
  • Prince Albert II of Monaco, among other dignitaries including from the World Health Organization (WHO) and the GVN.
  • Prince Albert II of Monaco said, “I am delighted to support and attend this symposium to improve pandemic preparedness here in Monaco and abroad.
  • We have a duty to remain vigilant, strengthen global governance, and strengthen infrastructure and healthcare systems.
  • Studies showed that phone apps tracking COVID cases and notifying those with exposure, significantly impacted hospitalization and death rates.

Safer and more Effective Brain Interfaces: First in Human Brain Recordings Achieved by Neurosoft Bioelectronics

Retrieved on: 
Tuesday, October 3, 2023
Oncology, Health, Medical Devices, Neurology, Health Technology, Clinical Trials, Biotechnology, Epilepsy, Swiss, Swiss Federal Institute of Technology, Digital Writing and Research Lab, Tinnitus, Deafness, Auditory cortex, Brain, Multimedia, Research, Biomarker, Trial of the century, Paralysis, DSM-IV codes, Wyss Center for Bio and Neuroengineering, Electrode, Patient, Traumatic brain injury, Memorial Hermann Health System, Hematoma, EPFL, FDA, Swiss Federal Institute of Aquatic Science and Technology, Safety, Hippocampus, Medical imaging, Medical device, Nursing

Two epileptic patients and one brain tumour patient have undergone a successful surgery, while detailed recordings were obtained in parallel from the surface of the brain.

Key Points: 
  • Two epileptic patients and one brain tumour patient have undergone a successful surgery, while detailed recordings were obtained in parallel from the surface of the brain.
  • Furthermore, the application of Neurosoft Bioelectronics’ electrodes presents the possibility of uncovering supplementary biomarkers which could significantly help in providing more effective and safer treatments of brain disorders for future patients.
  • Amidst these challenges, Neurosoft Bioelectronics' soft and elastic electrodes present themselves as a promising alternative to existing invasive solutions.
  • The Neurosoft Bioelectronics team has also been studying how these electrodes could address indications like severe tinnitus.

Spexis announces the appointment of Gonçalo Bernardes, Ph.D., as acting Head of Chemical Biology

Retrieved on: 
Thursday, September 28, 2023
Medicinal chemistry, Swiss, Swiss Federal Institute of Technology, Drug development, University, Therapy, ETH, Cancer, Research, Doctor of Philosophy, Trinity Hall, Cambridge, Chemistry, Entrepreneurship, Flagship Pioneering, Patient, Fellow, European Research Council, Atomic mass, Chemical biology, Library, Royal Society, Federal Institute for Materials Research and Testing, Pharmaceutical industry, Fine chemical, Nursing, Spexy Beast

Spexis announces the appointment of Gonçalo Bernardes, Ph.D., as acting Head of Chemical Biology

Key Points: 
  • Spexis announces the appointment of Gonçalo Bernardes, Ph.D., as acting Head of Chemical Biology
    Spexis announces the appointment of Gonçalo Bernardes, Ph.D., as acting Head of Chemical Biology
    Spexis AG (SIX: SPEX), a clinical-stage biopharmaceutical company focused on rare diseases and oncology, today announced that the company has appointed Gonçalo Bernardes, PhD, as acting Head of Chemical Biology.
  • “We are thrilled to welcome Gonçalo to Spexis, where we look forward to leveraging his expertise in chemical biology to advance the development of our novel macrocycle pipeline,” said Jeff Wager, M.D., Chairman & CEO of Spexis.
  • “Spexis remains committed to strengthening our leading position in macrocycle-based therapeutics with our two distinct and well characterized libraries, PEMFinder and MACROFinder.
  • Spexis continues to leverage its macrocycle platform into new therapeutic modalities and the company expects to provide further details on their progress later this year.

Spexis announces the appointment of Gonçalo Bernardes, Ph.D., as acting Head of Chemical Biology

Retrieved on: 
Thursday, September 28, 2023
Medicinal chemistry, Swiss, Swiss Federal Institute of Technology, Drug development, University, Therapy, ETH, Cancer, Research, Doctor of Philosophy, Trinity Hall, Cambridge, Chemistry, Entrepreneurship, Flagship Pioneering, Patient, Fellow, European Research Council, Atomic mass, Chemical biology, Library, Royal Society, Federal Institute of Science and Technology, Fine chemical, Pharmaceutical industry, Nursing, Spexy Beast

ALLSCHWIL, Switzerland, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Spexis AG (SIX: SPEX), a clinical-stage biopharmaceutical company focused on rare diseases and oncology, today announced that the company has appointed Gonçalo Bernardes, PhD, as acting Head of Chemical Biology.

Key Points: 
  • ALLSCHWIL, Switzerland, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Spexis AG (SIX: SPEX), a clinical-stage biopharmaceutical company focused on rare diseases and oncology, today announced that the company has appointed Gonçalo Bernardes, PhD, as acting Head of Chemical Biology.
  • “We are thrilled to welcome Gonçalo to Spexis, where we look forward to leveraging his expertise in chemical biology to advance the development of our novel macrocycle pipeline,” said Jeff Wager, M.D., Chairman & CEO of Spexis.
  • “Spexis remains committed to strengthening our leading position in macrocycle-based therapeutics with our two distinct and well characterized libraries, PEMFinder and MACROFinder.
  • Spexis continues to leverage its macrocycle platform into new therapeutic modalities and the company expects to provide further details on their progress later this year.

Dr. Hitto Kaufmann appointed Chief Scientific Officer of Hansa Biopharma

Retrieved on: 
Friday, September 1, 2023
Swiss Federal Institute of Technology, Swiss, Braunschweig, Scripps Research, Therapy, Biopharmaceutical, Ibete, Anticalin, CSO, Institute of technology, Biotechnology, Hansa, United States Air Force Scientific Advisory Board, Research, Science, Boehringer Ingelheim, Natural science, Executive Committee, Immunoglobulin G, Walter, Biology, Ghassan Hitto, Research fellow, Industrial Affairs Committee (Iceland), Technical University of Braunschweig, Swiss Federal Institute of Aquatic Science and Technology, Fine chemical, Sanofi

LUND, Sweden, Sept. 1, 2023 /PRNewswire/ -- Hansa Biopharma, "Hansa" (Nasdaq Stockholm: HNSA), a pioneer in enzyme technology for rare immunological conditions, announced today that Dr. Hitto Kaufmann has been appointed as Hansa's Chief Scientific Officer (CSO) effective 1 December 2023.

Key Points: 
  • LUND, Sweden, Sept. 1, 2023 /PRNewswire/ -- Hansa Biopharma, "Hansa" (Nasdaq Stockholm: HNSA), a pioneer in enzyme technology for rare immunological conditions, announced today that Dr. Hitto Kaufmann has been appointed as Hansa's Chief Scientific Officer (CSO) effective 1 December 2023.
  • Dr. Kaufmann joins Hansa from Pieris Pharmaceuticals where he has served as Chief Scientific Officer since 2019.
  • Søren Tulstrup, President and CEO, Hansa Biopharma said, "We are thrilled to welcome Hitto to Hansa at this pivotal time.
  • Dr. Hitto Kaufmann has served as Chief Scientific Officer at Pieris Pharmaceuticals since 2019.

Dr. Hitto Kaufmann appointed Chief Scientific Officer of Hansa Biopharma

Retrieved on: 
Friday, September 1, 2023
Swiss Federal Institute of Technology, Swiss, Braunschweig, Scripps Research, Therapy, Biopharmaceutical, Ibete, Anticalin, CSO, Institute of technology, Biotechnology, Hansa, United States Air Force Scientific Advisory Board, Research, Science, Boehringer Ingelheim, Natural science, Executive Committee, Immunoglobulin G, Walter, Biology, Ghassan Hitto, Research fellow, Industrial Affairs Committee (Iceland), Technical University of Braunschweig, Swiss Federal Institute of Aquatic Science and Technology, Fine chemical, Sanofi

LUND, Sweden, Sept. 1, 2023 /PRNewswire/ -- Hansa Biopharma, "Hansa" (Nasdaq Stockholm: HNSA), a pioneer in enzyme technology for rare immunological conditions, announced today that Dr. Hitto Kaufmann has been appointed as Hansa's Chief Scientific Officer (CSO) effective 1 December 2023.

Key Points: 
  • LUND, Sweden, Sept. 1, 2023 /PRNewswire/ -- Hansa Biopharma, "Hansa" (Nasdaq Stockholm: HNSA), a pioneer in enzyme technology for rare immunological conditions, announced today that Dr. Hitto Kaufmann has been appointed as Hansa's Chief Scientific Officer (CSO) effective 1 December 2023.
  • Dr. Kaufmann joins Hansa from Pieris Pharmaceuticals where he has served as Chief Scientific Officer since 2019.
  • Søren Tulstrup, President and CEO, Hansa Biopharma said, "We are thrilled to welcome Hitto to Hansa at this pivotal time.
  • Dr. Hitto Kaufmann has served as Chief Scientific Officer at Pieris Pharmaceuticals since 2019.

Shenzhen’s Guangming Science City Gathers International Scientists to Exchange Research Achievements and Academic Development Trends

Retrieved on: 
Monday, July 3, 2023
Technology, Research, Other Technology, Other Education, Continuing, University, Other Science, Science, Education, Swiss, Swiss Federal Institute of Technology, Tsinghua-Berkeley Shenzhen Institute, Culture, Sun, Multimedia, Seminar, YSF, Practice, Bright, International Seminar of Young Tibetologists, Advanced technology, The Seminar, Human, School, Material, City, Technical University of Crete, Federal Institute of Science and Technology, Southern University of Science and Technology, Management, Guangming District

Dozens of scientists from all over the world participated in the International Seminar on New Materials either offline or online on June 30, which was organized by Guangming Science City in Guangming District, Shenzhen Municipality, South China.

Key Points: 
  • Dozens of scientists from all over the world participated in the International Seminar on New Materials either offline or online on June 30, which was organized by Guangming Science City in Guangming District, Shenzhen Municipality, South China.
  • Shenzhen is one of the youngest cities in China, where Guangming Science City is synonymous with youth, vitality, openness, and diversity.
  • With a focus on the fields of life science, information, and materials, Guangming Science City is rolling forward the building of a series carrier of major science and technology innovation.
  • Guangming Science City is developing into a hub for scientific and industrial innovation with global influence.

The insurability of large-scale cyber risks: The symposium underlines the urgency of sustainably protecting the Swiss economy from major cyber attacks

Retrieved on: 
Monday, June 5, 2023
Helvetia, SME, Insurance, Swiss Federal Institute of Technology, Computer security, ETH, PwC, Politics, ETH Zurich, National Cyber Security Centre (Ireland), Federal, Government, Science, SGV, Werner Salzmann, ICT, SIA, Department of Computer Science of TU Darmstadt, Machine learning, NCSC, Council, Swiss Insurance Association, Swiss Federal Institute of Aquatic Science and Technology, SVP, Computer science, Property insurance, Tourism, Cryptocurrency

The insurability of large-scale cyber risks: The symposium underlines the urgency of sustainably protecting the Swiss economy from major cyber attacks

Key Points: 
  • The insurability of large-scale cyber risks: The symposium underlines the urgency of sustainably protecting the Swiss economy from major cyber attacks
    Helvetia's first cyber symposium tackles the "The challenges of overcoming the main cyber risks".
  • Enhancing cyber resilience through cooperation between business, government and science as a major locational advantage for Switzerland.
  • With cybercrime becoming one of the central top risks, the insurance gap for major cyber events is growing – both nationally and internationally.
  • Helvetia's "The challenges of overcoming the main cyber risks" symposium on 5 June 2023 aggressively brought this acute problem area into the public eye.

Nyxoah Appoints Christoph Eigenmann as Chief Commercial Officer

Retrieved on: 
Wednesday, May 10, 2023
Swiss Federal Institute of Technology, Mont-Saint-Guibert, CET, Senior, Obstructive sleep apnea, Marketing, Sales & Marketing Executives International, Biotechnology, Christoph, Christoph Eigenmann, Euronext, Chemical engineering, Patient, Growth, Johnson & Johnson, Neuro, Swiss Federal Institute of Aquatic Science and Technology, Pharmaceutical industry, Swiss

Mont-Saint-Guibert, Belgium – May 10, 2023, 10:05pm CET / 4:05pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced the appointment of Christoph Eigenmann as Chief Commercial Officer.

Key Points: 
  • Mont-Saint-Guibert, Belgium – May 10, 2023, 10:05pm CET / 4:05pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced the appointment of Christoph Eigenmann as Chief Commercial Officer.
  • Christoph will oversee commercial activities globally, be responsible for sales and marketing in existing markets, and new market development.
  • Christoph brings a wealth of experience in medical technologies to Nyxoah.
  • Christoph's years of experience in commercializing medical devices globally will be invaluable as Nyxoah prepares to enter the U.S. market and expands its commercial presence internationally,” commented Olivier Taelman, Nyxoah Chief Executive Officer.

HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committees 

Retrieved on: 
Wednesday, May 10, 2023
Molecular biology, The Elements of Style, Journal of Thoracic Oncology, Internet Technical Committee, Law, Lung cancer, Oncology, Article, Doctor of Philosophy, European Society for Medical Oncology, Audit committee, Teaching hospital, Professor, Retirement, Journal, University Hospital (Newark, New Jersey), Ageing, Health, Ludwig Cancer Research, Annals of Oncology, Swiss, SIX Swiss Exchange, Teaching, International Association, Research, Attention, Annals, Security (finance), Editor-in-chief, Woman, Swiss Federal Institute of Technology, ESMO, Medicine, NSCLC, US, HKEX, Letter, Swiss Federal Institute of Aquatic Science and Technology, Part, University of Lausanne, Galenica, Strategic Advisory Board for Intellectual Property Policy, HK, Management, Nursing

The Board of HUTCHMED is of the view that Professor Peters will make significant contributions to the Company.

Key Points: 
  • The Board of HUTCHMED is of the view that Professor Peters will make significant contributions to the Company.
  • Mr Simon To, Chairman of HUTCHMED said “On behalf of the Board, I would like to extend a warm welcome to Professor Peters to the Company.
  • Professor Peters is also an independent director of Galenica AG, which is listed on the SIX Swiss Exchange.
  • The director’s fees of Professor Peters as an Independent Non-executive Director, member of the Technical Committee and member of the Audit Committee of the Company under her appointment letter are US$76,000, US$8,000 and US$13,500 per annum respectively.